CoChat
Sign Up
Cited by 75

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Iron regulatory protein 1 promotes ferroptosis by sustaining cellular iron homeostasis in melanoma

Yao, Fengping, Cui, Xiaohong, Zhang, Ying, Bei, Zhuchun, Wang, Hongquan, Zhao, Dongxu, Wang, Hong, Yang, Yongfei·2021·Oncology Letters
DOI 10.3892/ol.2021.12918PMC PMC8299017
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2021.12918

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Erastin and RSL3 promote the expression of IRP1 and IRP2 in A375 melanoma cells. (A and B) mRNA levels of IRP1 and IRP2 were increased in (A) erastin- or (B) RSL3-treated A375 cells. (C and D) Protein levels of IRP1 and IRP2 were increased in (A) erastin- or (B) RSL3-treated A375 cells. Data are presented as the mean ± SD of three independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. IRP, iron regulatory protein.
Figure 1. Erastin and RSL3 promote the expression of IRP1 and IRP2 in A375 melanoma cells. (A and B) mRNA levels of IRP1 and IRP2 were increased in (A) erastin- or (B) RSL3-treated A375 cells. (C and D) Protein levels of IRP1 and IRP2 were increased in (A) erastin- or (B) RSL3-treated A375 cells. Data are presented as the mean ± SD of three independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. IRP, iron regulatory protein.CC BY-NC-ND · PubMed Central
Figure 2. Knockdown of IRP1 and IRP2 inhibits erastin- and RSL3-induced ferroptosis. (A) IRP1 and IRP2 knockdown inhibited erastin- and RSL3-induced ferroptotic cell death in A375 melanoma cells. (B) Knockdown of IRP1 and IRP2 inhibited erastin- and RSL3-induced iron accumulation in A375 cells. (C and D) Knockdown of IRP1 and IRP2 suppressed erastin- and RSL3-induced (C) MDA and (D) lipid ROS accumulation. The black line represents the control cells; the red line represents IRP1 knockdown; the green line represents IRP2knockdown and the blue line represents IRP1 and IRP2 knockdown. (E) Protein levels of IRP1 and IRP2 were detected following IRP1 and IRP2 knockdown. Data are presented as the mean ± SD of three independent experiments. *P<0.05; ***P<0.001; ****P<0.0001. IRP, iron regulatory protein. IRP, iron regulatory protein; sh, short hairpin RNA.
Figure 2. Knockdown of IRP1 and IRP2 inhibits erastin- and RSL3-induced ferroptosis. (A) IRP1 and IRP2 knockdown inhibited erastin- and RSL3-induced ferroptotic cell death in A375 melanoma cells. (B) Knockdown of IRP1 and IRP2 inhibited erastin- and RSL3-induced iron accumulation in A375 cells. (C and D) Knockdown of IRP1 and IRP2 suppressed erastin- and RSL3-induced (C) MDA and (D) lipid ROS accumulation. The black line represents the control cells; the red line represents IRP1 knockdown; the green line represents IRP2knockdown and the blue line represents IRP1 and IRP2 knockdown. (E) Protein levels of IRP1 and IRP2 were detected following IRP1 and IRP2 knockdown. Data are presented as the mean ± SD of three independent experiments. *P<0.05; ***P<0.001; ****P<0.0001. IRP, iron regulatory protein. IRP, iron regulatory protein; sh, short hairpin RNA.CC BY-NC-ND · PubMed Central
Figure 3. Overexpression of IRP1 and IRP2 promotes erastin- and RSL3-induced ferroptosis. (A) IRP1 and IRP2 overexpression promoted erastin- and RSL3-induced ferroptotic cell death in A375 melanoma cells. (B) Overexpression of IRP1 and IRP2 increased erastin- and RSL3-induced iron accumulation in A375 cells. (C and D) Overexpression of IRP1 and IRP2 promoted erastin- and RSL3-induced (C) MDA and (D) lipid ROS accumulation. The black line represents the control cells; the red line represents overexpression of IRP1; the green line represents overexpression of IRP2 andthe blue line represents overexpression of IRP1 and IRP2. (E) Protein levels of IRP1 and IRP2 were detected following IRP1 and IRP2 overexpression. Data are presented as the mean ± SD of three independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. IRP, iron regulatory protein; MDA, malondialdehyde; HA, hemagglutinin.
Figure 3. Overexpression of IRP1 and IRP2 promotes erastin- and RSL3-induced ferroptosis. (A) IRP1 and IRP2 overexpression promoted erastin- and RSL3-induced ferroptotic cell death in A375 melanoma cells. (B) Overexpression of IRP1 and IRP2 increased erastin- and RSL3-induced iron accumulation in A375 cells. (C and D) Overexpression of IRP1 and IRP2 promoted erastin- and RSL3-induced (C) MDA and (D) lipid ROS accumulation. The black line represents the control cells; the red line represents overexpression of IRP1; the green line represents overexpression of IRP2 andthe blue line represents overexpression of IRP1 and IRP2. (E) Protein levels of IRP1 and IRP2 were detected following IRP1 and IRP2 overexpression. Data are presented as the mean ± SD of three independent experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. IRP, iron regulatory protein; MDA, malondialdehyde; HA, hemagglutinin.CC BY-NC-ND · PubMed Central
Figure 4. Erastin and RSL3 promote the transition of ACO to IRP1. (A) ACO activity decreased significantly in A375 melanoma cells following erastin and RSL3 treatment. (B) Erastin and RSL3 promoted the IRE-binding activity of IRP1. (C) Erastin and RSL3 had no significant effect on the IRE-binding activity of IRP2. The relative abundances of IRP1-Flag and IRP2-Flag were analyzed by RNA immunoprecipitation. Data are presented as the mean ± SD of three independent experiments. ***P<0.001; ****P<0.0001. ACO, aconitase; IRP, iron regulatory protein; IRE, iron-responsive element; sh, short hairpin RNA; n.s., not significant.
Figure 4. Erastin and RSL3 promote the transition of ACO to IRP1. (A) ACO activity decreased significantly in A375 melanoma cells following erastin and RSL3 treatment. (B) Erastin and RSL3 promoted the IRE-binding activity of IRP1. (C) Erastin and RSL3 had no significant effect on the IRE-binding activity of IRP2. The relative abundances of IRP1-Flag and IRP2-Flag were analyzed by RNA immunoprecipitation. Data are presented as the mean ± SD of three independent experiments. ***P<0.001; ****P<0.0001. ACO, aconitase; IRP, iron regulatory protein; IRE, iron-responsive element; sh, short hairpin RNA; n.s., not significant.CC BY-NC-ND · PubMed Central
Figure 5. IRP1 is essential for the expression of iron-regulating proteins in ferroptosis. (A) Knockdown of IRP1 suppressed the mRNA expression levels expression of TFRC in A375 melanoma cells following erastin and RSL3 treatment. (B and C) Knockdown of IRP1 had no significant effect on the mRNA expression levels of (B) FPN and (C) FTH1 following erastin and RSL3 treatment. (D) Protein levels of TFRC, FPN and FTH1 in A375 cells treated with erastin or RSL3. Data are presented as the mean ± SD of three independent experiments. ***P<0.001; ****P<0.0001. IRP, iron regulatory protein; TFRC, transferrin receptor; FPN, ferroportin; FTH1, ferritin heavy chain 1; sh, short hairpin RNA; n.s., not significant.
Figure 5. IRP1 is essential for the expression of iron-regulating proteins in ferroptosis. (A) Knockdown of IRP1 suppressed the mRNA expression levels expression of TFRC in A375 melanoma cells following erastin and RSL3 treatment. (B and C) Knockdown of IRP1 had no significant effect on the mRNA expression levels of (B) FPN and (C) FTH1 following erastin and RSL3 treatment. (D) Protein levels of TFRC, FPN and FTH1 in A375 cells treated with erastin or RSL3. Data are presented as the mean ± SD of three independent experiments. ***P<0.001; ****P<0.0001. IRP, iron regulatory protein; TFRC, transferrin receptor; FPN, ferroportin; FTH1, ferritin heavy chain 1; sh, short hairpin RNA; n.s., not significant.CC BY-NC-ND · PubMed Central
Figure 6. IRP1 function in ferroptosis depends on TFRC, FPN and FTH1. (A) Overexpression of TFRC and knockdown of FPN and FTH1 enhanced erastin- and RSL3-induced ferroptotic cell death in IRP1 knockdown A375 melanoma cells. (B) Overexpression of TFRC and knockdown of FPN and FTH1 promoted erastin- and RSL3-induced iron accumulation in IRP1 knockdown A375 melanoma cells. (C and D) Overexpression of TFRC and knockdown of FPN and FTH1 promoted erastin- and RSL3-induced (C) MDA accumulation and (D) lipid ROS accumulation in IRP1 knockdown A375 melanoma cells. The black line represents the control cells; the red line represents IRP1 knockdown; the green line represents overexpression of TFRC and IRP1 knockdown; the blue line represents the FPN, FTH1 and IRP1 knockdown and the orange line represents overexpression of TFRC and FPN, FTH1 and IRP1 knockdown. (E) Protein levels of IRP1, TFRC, FPN and FTH1 in A375 cells transfected with the indicated constructs. Data are presented as the mean ± SD of three independent experiments. *P<0.05; **P<0.01; ***P<0.001. IRP, iron regulatory protein; TFRC, transferrin receptor; FPN, ferroportin; FTH1, ferritin heavy chain 1; sh, short hairpin RNA; MDA, malondialdehyde; n.s., not significant.
Figure 6. IRP1 function in ferroptosis depends on TFRC, FPN and FTH1. (A) Overexpression of TFRC and knockdown of FPN and FTH1 enhanced erastin- and RSL3-induced ferroptotic cell death in IRP1 knockdown A375 melanoma cells. (B) Overexpression of TFRC and knockdown of FPN and FTH1 promoted erastin- and RSL3-induced iron accumulation in IRP1 knockdown A375 melanoma cells. (C and D) Overexpression of TFRC and knockdown of FPN and FTH1 promoted erastin- and RSL3-induced (C) MDA accumulation and (D) lipid ROS accumulation in IRP1 knockdown A375 melanoma cells. The black line represents the control cells; the red line represents IRP1 knockdown; the green line represents overexpression of TFRC and IRP1 knockdown; the blue line represents the FPN, FTH1 and IRP1 knockdown and the orange line represents overexpression of TFRC and FPN, FTH1 and IRP1 knockdown. (E) Protein levels of IRP1, TFRC, FPN and FTH1 in A375 cells transfected with the indicated constructs. Data are presented as the mean ± SD of three independent experiments. *P<0.05; **P<0.01; ***P<0.001. IRP, iron regulatory protein; TFRC, transferrin receptor; FPN, ferroportin; FTH1, ferritin heavy chain 1; sh, short hairpin RNA; MDA, malondialdehyde; n.s., not significant.CC BY-NC-ND · PubMed Central
Figure 7. Schematic depicting IRP1-mediated ferroptosis in melanoma cells. The Fe3+ transported into cells by TFRC and the Fe2+ released through ferritinophagy are the main sources of iron pools. In wild-type cells, erastin- and RSL3-induced IRP1 promotes the expression of TFRC and suppresses the expression of FPN and ferritin, which increases the intracellular Fe2+ levels and promotes ferroptosis. In the absence of IRP1, these effects are reversed, resulting in significantly decreased intracellular Fe2+ levels, thus suppressing erastin- and RSL3-induced ferroptosis. IRP, iron regulatory protein; TFRC, transferrin receptor; FPN, ferroportin; FTH1, ferritin heavy chain 1; ROS, reactive oxidant species; FTL, ferritin light chain.
Figure 7. Schematic depicting IRP1-mediated ferroptosis in melanoma cells. The Fe3+ transported into cells by TFRC and the Fe2+ released through ferritinophagy are the main sources of iron pools. In wild-type cells, erastin- and RSL3-induced IRP1 promotes the expression of TFRC and suppresses the expression of FPN and ferritin, which increases the intracellular Fe2+ levels and promotes ferroptosis. In the absence of IRP1, these effects are reversed, resulting in significantly decreased intracellular Fe2+ levels, thus suppressing erastin- and RSL3-induced ferroptosis. IRP, iron regulatory protein; TFRC, transferrin receptor; FPN, ferroportin; FTH1, ferritin heavy chain 1; ROS, reactive oxidant species; FTL, ferritin light chain.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 55

  1. Hentze, 2010, Two to tango: Regulation of Mammalian iron metabolism, Cell, 142, 24, 10.1016/j.cell.2010.06.028 · DOI · Paper page
  2. Datz, 2017, Iron overload and non-alcoholic fatty liver disease, Minerva Endocrinol, 42, 173, 10.23736/S0391-1977.16.02565-7 · DOI
  3. Babitt, 2012, Mechanisms of anemia in CKD, J Am Soc Nephrol, 23, 1631, 10.1681/ASN.2011111078 · DOI · Paper page
  4. Keith, 2004, Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization, Arch Intern Med, 164, 659, 10.1001/archinte.164.6.659 · DOI
  5. Bush, 2003, The metallobiology of Alzheimer's disease, Trends Neurosci, 26, 207, 10.1016/S0166-2236(03)00067-5 · DOI · Paper page
  6. Singh, 2019, Oxidative Stress: A Key Modulator in Neurodegenerative Diseases, Molecules, 24, 1583, 10.3390/molecules24081583 · DOI
  7. Zager, 2006, Parenteral iron compounds: Potent oxidants but mainstays of anemia management in chronic renal disease, Clin J Am Soc Nephrol, S24, 10.2215/CJN.01410406 · DOI
  8. Jin, 2011, Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease, Brain, 134, 50, 10.1093/brain/awq319 · DOI
  9. Britton, 2016, Iron and non-alcoholic fatty liver disease, World J Gastroenterol, 22, 8112, 10.3748/wjg.v22.i36.8112 · DOI
  10. Jiang, 2004, Body iron stores in relation to risk of type 2 diabetes in apparently healthy women, JAMA, 291, 711, 10.1001/jama.291.6.711 · DOI · Paper page
  11. Wilkinson, 2014, The IRP/IRE system in vivo: Insights from mouse models, Front Pharmacol, 5, 176, 10.3389/fphar.2014.00176 · DOI · Paper page
  12. Brown, 2002, Detection of a [3Fe-4S] cluster intermediate of cytosolic aconitase in yeast expressing iron regulatory protein 1. Insights into the mechanism of Fe-S cluster cycling, J Biol Chem, 277, 7246, 10.1074/jbc.M110282200 · DOI
  13. Lushchak, 2014, Aconitase post-translational modification as a key in linkage between Krebs cycle, iron homeostasis, redox signaling, and metabolism of reactive oxygen species, Redox Rep, 19, 8, 10.1179/1351000213Y.0000000073 · DOI
  14. Tong, 2007, Metabolic regulation of citrate and iron by aconitases: Role of iron-sulfur cluster biogenesis, Biometals, 20, 549, 10.1007/s10534-006-9047-6 · DOI
  15. Meyron-Holtz, 2004, Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis, EMBO J, 23, 386, 10.1038/sj.emboj.7600041 · DOI · Paper page
  16. Meyron-Holtz, 2004, Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo, Science, 306, 2087, 10.1126/science.1103786 · DOI
  17. Ghosh, 2008, Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice, Proc Natl Acad Sci USA, 105, 12028, 10.1073/pnas.0805361105 · DOI
  18. Stys, 2011, Iron regulatory protein 1 outcompetes iron regulatory protein 2 in regulating cellular iron homeostasis in response to nitric oxide, J Biol Chem, 286, 22846, 10.1074/jbc.M111.231902 · DOI
  19. Dev, 2015, Role of extracellular Hydrogen peroxide in regulation of iron homeostasis genes in neuronal cells: Implication in iron accumulation, Free Radic Biol Med, 86, 78, 10.1016/j.freeradbiomed.2015.05.025 · DOI
  20. Dixon, 2012, Ferroptosis: An iron-dependent form of nonapoptotic cell death, Cell, 149, 1060, 10.1016/j.cell.2012.03.042 · DOI · Paper page
  21. Dolma, 2003, Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells, Cancer Cell, 3, 285, 10.1016/S1535-6108(03)00050-3 · DOI · Paper page
  22. Yang, 2014, Regulation of ferroptotic cancer cell death by GPX4, Cell, 156, 317, 10.1016/j.cell.2013.12.010 · DOI · Paper page
  23. Wang, 2017, Characterization of ferroptosis in murine models of hemochromatosis, Hepatology, 66, 449, 10.1002/hep.29117 · DOI
  24. Geng, 2018, Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells, Eur Rev Med Pharmacol Sci, 22, 3826
  25. Gao, 2015, Glutaminolysis and transferrin regulate ferroptosis, Mol Cell, 59, 298, 10.1016/j.molcel.2015.06.011 · DOI · Paper page
  26. Zhang, 2018, Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells, Autophagy, 14, 2083, 10.1080/15548627.2018.1503146 · DOI
  27. Lin, 2018, Simultaneous Fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy, Angew Chem Int Ed Engl, 57, 4902, 10.1002/anie.201712027 · DOI
  28. Sui, 2019, Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells, Cell Death Dis, 10, 331, 10.1038/s41419-019-1564-7 · DOI
  29. Siegel, 2020, Cancer statistics, 2020, CA: Cancer J Clin, 70, 7
  30. Brenner, 2008, The protective role of melanin against UV damage in human skin, Photochem Photobiol, 84, 539, 10.1111/j.1751-1097.2007.00226.x · DOI · Paper page
  31. Lang, 2019, Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11, Cancer Discov, 9, 1673, 10.1158/2159-8290.CD-19-0338 · DOI
  32. Sato, 2020, Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and markedly increases survival rates of mice, Int J Cancer, 147, 3224, 10.1002/ijc.33262 · DOI
  33. Konieczkowski, 2014, A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors, Cancer Discov, 4, 816, 10.1158/2159-8290.CD-13-0424 · DOI
  34. Luo, 2018, miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma, Cell Death Differ, 25, 1457, 10.1038/s41418-017-0053-8 · DOI · Paper page
  35. Tsoi, 2018, Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress, Cancer Cell, 33, 890, 10.1016/j.ccell.2018.03.017 · DOI · Paper page
  36. Miyazawa, 2019, Perturbation of iron metabolism by cisplatin through inhibition of iron regulatory protein 2, Cell Chem Biol, 26, 85, 10.1016/j.chembiol.2018.10.009 · DOI
  37. Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods, 25, 402, 10.1006/meth.2001.1262 · DOI · Paper page
  38. Philpott, 1994, The bifunctional iron-responsive element binding protein/cytosolic aconitase: The role of active-site residues in ligand binding and regulation, Proc Natl Acad Sci USA, 91, 7321, 10.1073/pnas.91.15.7321 · DOI
  39. Eisenstein, 2000, Iron regulatory proteins and the molecular control of mammalian iron metabolism, Annu Rev Nutr, 20, 627, 10.1146/annurev.nutr.20.1.627 · DOI
  40. LaVaute, 2001, Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice, Nat Genet, 27, 209, 10.1038/84859 · DOI · Paper page
  41. Velsor, 2006, Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice, Am J Respir Cell Mol Biol, 35, 579, 10.1165/rcmb.2005-0473OC · DOI
  42. Gardner, 2002, Aconitase: Sensitive target and measure of superoxide, Methods Enzymol, 349, 9, 10.1016/S0076-6879(02)49317-2 · DOI
  43. Gardner, 1994, Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs, Proc Natl Acad Sci USA, 91, 12248, 10.1073/pnas.91.25.12248 · DOI
  44. Funauchi, 2015, Regulation of iron homeostasis by the p53-ISCU pathway, Sci Rep, 5, 16497, 10.1038/srep16497 · DOI
  45. Zhang, 2008, Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest, J Biol Chem, 283, 33911, 10.1074/jbc.M806432200 · DOI
  46. Thompson, 2020, Distinct TP53 mutation types exhibit increased sensitivity to ferroptosis independently of changes in iron regulatory protein activity, Int J Mol Sci, 21, 6751, 10.3390/ijms21186751 · DOI
  47. Ou, 2016, Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses, Proc Natl Acad Sci USA, 113, E6806, 10.1073/pnas.1607152113 · DOI
  48. Jennis, 2016, An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model, Genes Dev, 30, 918, 10.1101/gad.275891.115 · DOI
  49. Wang, 2016, Acetylation is crucial for p53-mediated ferroptosis and tumor suppression, Cell Rep, 17, 366, 10.1016/j.celrep.2016.09.022 · DOI
  50. Li, 2021, PDT-Enhanced ferroptosis by a polymer nanoparticle with pH-activated singlet oxygen generation and superb biocompatibility for cancer therapy, Biomacromolecules, 22, 1167, 10.1021/acs.biomac.0c01679 · DOI
  51. Jasim, 2019, Ultrastable and biofunctionalizable conjugated polymer nanoparticles with encapsulated iron for ferroptosis assisted chemodynamic therapy, Mol Pharm, 16, 4852, 10.1021/acs.molpharmaceut.9b00737 · DOI
  52. Wang, 2018, Iron metabolism in cancer, Int J Mol Sci, 20, 95, 10.3390/ijms20010095 · DOI
  53. Bian, 2018, Ferritin level prospectively predicts hepatocarcinogenesis in patients with chronic hepatitis B virus infection, Oncol Lett, 16, 3499
  54. Song, 2018, Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: A retrospective cohort study, BMC Complement Altern Med, 18, 176, 10.1186/s12906-018-2240-7 · DOI
  55. Guo, 2015, An important role of the hepcidin-ferroportin signaling in affecting tumor growth and metastasis, Acta Biochim Biophys Sin (Shanghai), 47, 703, 10.1093/abbs/gmv063 · DOI

Cited by

Sorted by citations

See all 75

Metadata

Authors
Yao, F., Cui, X., Zhang, Y., Bei, Z., Wang, H., Zhao, D., Wang, H., & Yang, Y.
Affiliations
  • School of Life Science, Beijing Institute of Technology, Beijing 100081, P.R. China
  • Psychiatry Department, Shanxi Bethune Hospital, Taiyuan, Shanxi 030000, P.R. China
  • State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, P.R. China
Venue
Oncology Letters
Publisher
Spandidos Publications
Published
2021-07-12
Volume
22
Issue
3
ISSN
  • 1792-1074
  • 1792-1082
DOI
10.3892/ol.2021.12918
PMC
PMC8299017
Cited by
75
References
7

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review